title: Ariad Pharmaceutical's ninja cancer drug inhibits armies of mutants.
authors.affiliation: wendywolfson@nasw.org
authors.forename: Wendy
authors.initials: W
authors.lastname: Wolfson
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology*; D004345:Drug Industry; D016044:Fusion Proteins, bcr-abl / Q000037:antagonists & inhibitors* / Q000235:genetics* / Q000378:metabolism; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D050505:Mutant Proteins / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D047428:Protein Kinase Inhibitors / Q000494:pharmacology*; D011724:Pyridazines / Q000494:pharmacology*
chemical_list: D000970:Antineoplastic Agents; D007093:Imidazoles; D050505:Mutant Proteins; D047428:Protein Kinase Inhibitors; D011724:Pyridazines; C545373:ponatinib; D016044:Fusion Proteins, bcr-abl